Selected research
Industry Research
Human cytomegalovirus 65 kDa Phosphoprotein Industry Research Report 2026
Market perspective
The global Human cytomegalovirus 65 kDa Phosphoprotein market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
The North America market for Human cytomegalovirus 65 kDa Phosphoprotein is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026–2032.
The Europe market for Human cytomegalovirus 65 kDa Phosphoprotein is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032.
Read the full market overview
The Asia Pacific market for Human cytomegalovirus 65 kDa Phosphoprotein is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032.
Leading global manufacturers of Human cytomegalovirus 65 kDa Phosphoprotein include Astellas Pharma Inc, Hookipa Biotech AG, Immunomic Therapeutics Inc, Vakzine Projekt Management GmbH, Vaximm AG, VBI Vaccines Inc and Vical Inc, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
This report quantifies the global Human cytomegalovirus 65 kDa Phosphoprotein market in terms of revenue (US$ million) and, where applicable, sales volume (K Units), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/K Units) and concentration ratios (CR5/CR10).
The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.
Key Companies & Market Share Insights
This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Human cytomegalovirus 65 kDa Phosphoprotein Market by Company
Astellas Pharma Inc
Hookipa Biotech AG
Immunomic Therapeutics Inc
Vakzine Projekt Management GmbH
Vaximm AG
VBI Vaccines Inc
Vical Inc
Human cytomegalovirus 65 kDa Phosphoprotein Segment by Type
HB-101
ASP-0113
PepVax
CyMVectin
Others
Human cytomegalovirus 65 kDa Phosphoprotein Segment by Application
Hemotaological Tumor
Kidney Transplant Rejection
Brain Tumor
Liver Transplant Rejection
Others
Human cytomegalovirus 65 kDa Phosphoprotein Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Netherlands
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Human cytomegalovirus 65 kDa Phosphoprotein market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Human cytomegalovirus 65 kDa Phosphoprotein and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Human cytomegalovirus 65 kDa Phosphoprotein.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Detailed analysis of Human cytomegalovirus 65 kDa Phosphoprotein manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.
Chapter 5: Production/output, value of Human cytomegalovirus 65 kDa Phosphoprotein by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.
Chapter 6: Consumption of Human cytomegalovirus 65 kDa Phosphoprotein in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.
Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 11: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- HB-101
- ASP-0113
- PepVax
- CyMVectin
- Others
Applications
- Hemotaological Tumor
- Kidney Transplant Rejection
- Brain Tumor
- Liver Transplant Rejection
- Others
Companies covered
- Astellas Pharma Inc
- Hookipa Biotech AG
- Immunomic Therapeutics Inc
- Vakzine Projekt Management GmbH
- Vaximm AG
- VBI Vaccines Inc
- Vical Inc
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Global Market Growth Prospects
- 2.2.1 Global Human cytomegalovirus 65 kDa Phosphoprotein Market Size (2021-2032)
- 2.2.2 Global Human cytomegalovirus 65 kDa Phosphoprotein Sales (2021-2032)
- 2.2.3 Global Human cytomegalovirus 65 kDa Phosphoprotein Market Average Price (2021-2032)
- 2.3 Human cytomegalovirus 65 kDa Phosphoprotein by Type
- 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
- 2.3.2 HB-101
- 2.3.3 ASP-0113
- 2.3.4 PepVax
- 2.3.5 CyMVectin
- 2.3.6 Others
- 2.4 Human cytomegalovirus 65 kDa Phosphoprotein by Application
- 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.4.2 Hemotaological Tumor
- 2.4.3 Kidney Transplant Rejection
- 2.4.4 Brain Tumor
- 2.4.5 Liver Transplant Rejection
- 2.4.6 Others
3 Market Competitive Landscape by Manufacturers
- 3.1 Global Human cytomegalovirus 65 kDa Phosphoprotein Market Competitive Situation by Manufacturers (2021 Versus 2025)
- 3.2 Global Human cytomegalovirus 65 kDa Phosphoprotein Sales (K Units) of Manufacturers (2021-2026)
- 3.3 Global Human cytomegalovirus 65 kDa Phosphoprotein Revenue of Manufacturers (2021-2026)
- 3.4 Global Human cytomegalovirus 65 kDa Phosphoprotein Average Price by Manufacturers (2021-2026)
- 3.5 Global Human cytomegalovirus 65 kDa Phosphoprotein Industry Ranking, 2024 VS 2025 VS 2026
- 3.6 Global Manufacturers of Human cytomegalovirus 65 kDa Phosphoprotein, Manufacturing Sites & Headquarters
- 3.7 Global Manufacturers of Human cytomegalovirus 65 kDa Phosphoprotein, Product Type & Application
- 3.8 Global Manufacturers of Human cytomegalovirus 65 kDa Phosphoprotein, Established Date
- 3.9 Global Human cytomegalovirus 65 kDa Phosphoprotein Market CR5 and HHI
- 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
- 4.1 Astellas Pharma Inc
- 4.1.1 Astellas Pharma Inc Company Information
- 4.1.2 Astellas Pharma Inc Business Overview
- 4.1.3 Astellas Pharma Inc Human cytomegalovirus 65 kDa Phosphoprotein Sales, Revenue and Gross Margin (2021-2026)
- 4.1.4 Astellas Pharma Inc Human cytomegalovirus 65 kDa Phosphoprotein Product Portfolio
- 4.1.5 Astellas Pharma Inc Recent Developments
- 4.2 Hookipa Biotech AG
- 4.2.1 Hookipa Biotech AG Company Information
- 4.2.2 Hookipa Biotech AG Business Overview
- 4.2.3 Hookipa Biotech AG Human cytomegalovirus 65 kDa Phosphoprotein Sales, Revenue and Gross Margin (2021-2026)
- 4.2.4 Hookipa Biotech AG Human cytomegalovirus 65 kDa Phosphoprotein Product Portfolio
- 4.2.5 Hookipa Biotech AG Recent Developments
- 4.3 Immunomic Therapeutics Inc
- 4.3.1 Immunomic Therapeutics Inc Company Information
- 4.3.2 Immunomic Therapeutics Inc Business Overview
- 4.3.3 Immunomic Therapeutics Inc Human cytomegalovirus 65 kDa Phosphoprotein Sales, Revenue and Gross Margin (2021-2026)
- 4.3.4 Immunomic Therapeutics Inc Human cytomegalovirus 65 kDa Phosphoprotein Product Portfolio
- 4.3.5 Immunomic Therapeutics Inc Recent Developments
- 4.4 Vakzine Projekt Management GmbH
- 4.4.1 Vakzine Projekt Management GmbH Company Information
- 4.4.2 Vakzine Projekt Management GmbH Business Overview
- 4.4.3 Vakzine Projekt Management GmbH Human cytomegalovirus 65 kDa Phosphoprotein Sales, Revenue and Gross Margin (2021-2026)
- 4.4.4 Vakzine Projekt Management GmbH Human cytomegalovirus 65 kDa Phosphoprotein Product Portfolio
- 4.4.5 Vakzine Projekt Management GmbH Recent Developments
- 4.5 Vaximm AG
- 4.5.1 Vaximm AG Company Information
- 4.5.2 Vaximm AG Business Overview
- 4.5.3 Vaximm AG Human cytomegalovirus 65 kDa Phosphoprotein Sales, Revenue and Gross Margin (2021-2026)
- 4.5.4 Vaximm AG Human cytomegalovirus 65 kDa Phosphoprotein Product Portfolio
- 4.5.5 Vaximm AG Recent Developments
- 4.6 VBI Vaccines Inc
- 4.6.1 VBI Vaccines Inc Company Information
- 4.6.2 VBI Vaccines Inc Business Overview
- 4.6.3 VBI Vaccines Inc Human cytomegalovirus 65 kDa Phosphoprotein Sales, Revenue and Gross Margin (2021-2026)
- 4.6.4 VBI Vaccines Inc Human cytomegalovirus 65 kDa Phosphoprotein Product Portfolio
- 4.6.5 VBI Vaccines Inc Recent Developments
- 4.7 Vical Inc
- 4.7.1 Vical Inc Company Information
- 4.7.2 Vical Inc Business Overview
- 4.7.3 Vical Inc Human cytomegalovirus 65 kDa Phosphoprotein Sales, Revenue and Gross Margin (2021-2026)
- 4.7.4 Vical Inc Human cytomegalovirus 65 kDa Phosphoprotein Product Portfolio
- 4.7.5 Vical Inc Recent Developments
5 Global Human cytomegalovirus 65 kDa Phosphoprotein Market Scenario by Region
- 5.1 Global Human cytomegalovirus 65 kDa Phosphoprotein Market Size by Region: 2021 VS 2025 VS 2032
- 5.2 Global Human cytomegalovirus 65 kDa Phosphoprotein Sales by Region: 2021-2032
- 5.2.1 Global Human cytomegalovirus 65 kDa Phosphoprotein Sales by Region: 2021-2026
- 5.2.2 Global Human cytomegalovirus 65 kDa Phosphoprotein Sales by Region: 2027-2032
- 5.3 Global Human cytomegalovirus 65 kDa Phosphoprotein Revenue by Region: 2021-2032
- 5.3.1 Global Human cytomegalovirus 65 kDa Phosphoprotein Revenue by Region: 2021-2026
- 5.3.2 Global Human cytomegalovirus 65 kDa Phosphoprotein Revenue by Region: 2027-2032
- 5.4 North America Human cytomegalovirus 65 kDa Phosphoprotein Market Facts & Figures by Country
- 5.4.1 North America Human cytomegalovirus 65 kDa Phosphoprotein Market Size by Country: 2021 VS 2025 VS 2032
- 5.4.2 North America Human cytomegalovirus 65 kDa Phosphoprotein Sales by Country (2021-2032)
- 5.4.3 North America Human cytomegalovirus 65 kDa Phosphoprotein Revenue by Country (2021-2032)
- 5.4.4 United States
- 5.4.5 Canada
- 5.5 Europe Human cytomegalovirus 65 kDa Phosphoprotein Market Facts & Figures by Country
- 5.5.1 Europe Human cytomegalovirus 65 kDa Phosphoprotein Market Size by Country: 2021 VS 2025 VS 2032
- 5.5.2 Europe Human cytomegalovirus 65 kDa Phosphoprotein Sales by Country (2021-2032)
- 5.5.3 Europe Human cytomegalovirus 65 kDa Phosphoprotein Revenue by Country (2021-2032)
- 5.5.4 Germany
- 5.5.5 France
- 5.5.6 U.K.
- 5.5.7 Italy
- 5.5.8 Netherlands
- 5.6 Asia Pacific Human cytomegalovirus 65 kDa Phosphoprotein Market Facts & Figures by Country
- 5.6.1 Asia Pacific Human cytomegalovirus 65 kDa Phosphoprotein Market Size by Country: 2021 VS 2025 VS 2032
- 5.6.2 Asia Pacific Human cytomegalovirus 65 kDa Phosphoprotein Sales by Country (2021-2032)
- 5.6.3 Asia Pacific Human cytomegalovirus 65 kDa Phosphoprotein Revenue by Country (2021-2032)
- 5.6.4 China
- 5.6.5 Japan
- 5.6.6 South Korea
- 5.6.7 India
- 5.6.8 Australia
- 5.6.9 China Taiwan
- 5.6.10 Southeast Asia
- 5.7 South America Human cytomegalovirus 65 kDa Phosphoprotein Market Facts & Figures by Country
- 5.7.1 South America Human cytomegalovirus 65 kDa Phosphoprotein Market Size by Country: 2021 VS 2025 VS 2032
- 5.7.2 South America Human cytomegalovirus 65 kDa Phosphoprotein Sales by Country (2021-2032)
- 5.7.3 South America Human cytomegalovirus 65 kDa Phosphoprotein Revenue by Country (2021-2032)
- 5.7.4 Mexico
- 5.7.5 Brazil
- 5.7.6 Argentina
- 5.8 Middle East and Africa Human cytomegalovirus 65 kDa Phosphoprotein Market Facts & Figures by Country
- 5.8.1 Middle East and Africa Human cytomegalovirus 65 kDa Phosphoprotein Market Size by Country: 2021 VS 2025 VS 2032
- 5.8.2 Middle East and Africa Human cytomegalovirus 65 kDa Phosphoprotein Sales by Country (2021-2032)
- 5.8.3 Middle East and Africa Human cytomegalovirus 65 kDa Phosphoprotein Revenue by Country (2021-2032)
- 5.8.4 Turkey
- 5.8.5 Saudi Arabia
- 5.8.6 UAE
6 Segment by Type
- 6.1 Global Human cytomegalovirus 65 kDa Phosphoprotein Sales by Type (2021-2032)
- 6.1.1 Global Human cytomegalovirus 65 kDa Phosphoprotein Sales by Type (2021-2032) & (K Units)
- 6.1.2 Global Human cytomegalovirus 65 kDa Phosphoprotein Sales Market Share by Type (2021-2032)
- 6.2 Global Human cytomegalovirus 65 kDa Phosphoprotein Revenue by Type (2021-2032)
- 6.2.1 Global Human cytomegalovirus 65 kDa Phosphoprotein Sales by Type (2021-2032) & (US$ Million)
- 6.2.2 Global Human cytomegalovirus 65 kDa Phosphoprotein Revenue Market Share by Type (2021-2032)
- 6.3 Global Human cytomegalovirus 65 kDa Phosphoprotein Price by Type (2021-2032)
7 Segment by Application
- 7.1 Global Human cytomegalovirus 65 kDa Phosphoprotein Sales by Application (2021-2032)
- 7.1.1 Global Human cytomegalovirus 65 kDa Phosphoprotein Sales by Application (2021-2032) & (K Units)
- 7.1.2 Global Human cytomegalovirus 65 kDa Phosphoprotein Sales Market Share by Application (2021-2032)
- 7.2 Global Human cytomegalovirus 65 kDa Phosphoprotein Revenue by Application (2021-2032)
- 7.2.1 Global Human cytomegalovirus 65 kDa Phosphoprotein Sales by Application (2021-2032) & (US$ Million)
- 7.2.2 Global Human cytomegalovirus 65 kDa Phosphoprotein Revenue Market Share by Application (2021-2032)
- 7.3 Global Human cytomegalovirus 65 kDa Phosphoprotein Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
- 8.1 Human cytomegalovirus 65 kDa Phosphoprotein Value Chain Analysis
- 8.1.1 Human cytomegalovirus 65 kDa Phosphoprotein Key Raw Materials
- 8.1.2 Raw Materials Key Suppliers
- 8.1.3 Human cytomegalovirus 65 kDa Phosphoprotein Production Mode & Process
- 8.2 Human cytomegalovirus 65 kDa Phosphoprotein Sales Channels Analysis
- 8.2.1 Direct Comparison with Distribution Share
- 8.2.2 Human cytomegalovirus 65 kDa Phosphoprotein Distributors
- 8.2.3 Human cytomegalovirus 65 kDa Phosphoprotein Customers
9 Global Human cytomegalovirus 65 kDa Phosphoprotein Analyzing Market Dynamics
- 9.1 Human cytomegalovirus 65 kDa Phosphoprotein Industry Trends
- 9.2 Human cytomegalovirus 65 kDa Phosphoprotein Industry Drivers
- 9.3 Human cytomegalovirus 65 kDa Phosphoprotein Industry Opportunities and Challenges
- 9.4 Human cytomegalovirus 65 kDa Phosphoprotein Industry Restraints
10 Report Conclusion
11 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst